Trajectories of Drug Treatment and Illicit Opioid Use in the AIDS Linked to the IntraVenous Experience Cohort, 2014-2019

Overview

Journal Int J Drug Policy

Publisher Elsevier

Specialties Psychiatry
Public Health

Date 2023 Jul 10

PMID 37429162

Authors

Jacqueline E Rudolph

Javier A Cepeda

Jacquie Astemborski

Gregory D Kirk

Shruti H Mehta

Becky L Genberg

Affiliations

Soon will be listed here.

Abstract

Background: Medication for opioid use disorder (MOUD) is an effective intervention to combat opioid use disorder and overdose, yet there is limited understanding of engagement in treatment over time in the community, contextualized by ongoing substance use. We aimed to identify concurrent trajectories of methadone prescriptions, buprenorphine prescriptions, and illicit opioid use among older adults with a history of injection drug use.

Methods: We used data on 887 participants from the AIDS Linked to the IntraVenous Experience cohort, who were engaged in the study in 2013 and attended ≥1 visit during follow-up (2014-2019). Outcomes were self-reported MOUD prescription and illicit opioid use in the last 6 months. To identify concurrent trajectories in all 3 outcomes, we used group-based multi-trajectory modeling. We examined participant characteristics, including sociodemographics, HIV status, and other substance use, overall and by cluster.

Results: We identified 4 trajectory clusters: (1) no MOUD and no illicit opioid use (43%); (2) buprenorphine and some illicit opioid use (11%); (3) methadone and no illicit opioid use (28%); and (4) some methadone and illicit opioid use (18%). While prevalence of each outcome was stable across time, transitions on/off treatment or on/off illicit opioid use occurred, with the rate of transition varying by cluster. The rate of transition was highest in Cluster 3 (0.74/person-year) and lowest in Cluster 1 (0.18/person-year). We saw differences in participant characteristics by cluster, including that the buprenorphine cluster had the highest proportion of people with HIV and participants who identified as non-Hispanic Black.

Conclusions: Most participants had discontinued illicit opioid use and were also not accessing MOUD. Trajectories defined by engagement with buprenorphine or methadone had distinct sociodemographic and behavioral characteristics, indicating that tailored interventions to expand access to both types of treatment are likely needed to reduce harms associated with untreated opioid use disorder.

Citing Articles

Association of inadequate sleep with mortality among persons who inject drugs.

Sun J, Hsu H, Rabinowitz J, Sosnowski D, Piggott D, Mehta S Sleep Health. 2024; 10(6):651-657.

PMID: 39278806 PMC: 11624996. DOI: 10.1016/j.sleh.2024.07.008.

Structural and social changes due to the COVID-19 pandemic and their impact on engagement in substance use disorder treatment services: a qualitative study among people with a recent history of injection drug use in Baltimore, Maryland.

Patel E, Grieb S, Winiker A, Ching J, Schluth C, Mehta S Harm Reduct J. 2024; 21(1):91.

PMID: 38720307 PMC: 11077846. DOI: 10.1186/s12954-024-01008-8.

Longitudinal patterns of use of stimulants and opioids in the AIDS linked to the IntraVenous experience cohort, 2005-2019.

Rudolph J, Cepeda J, Astemborski J, Kirk G, Mehta S, German D Int J Drug Policy. 2024; 126:104364.

PMID: 38408416 PMC: 11056308. DOI: 10.1016/j.drugpo.2024.104364.

References

Santo Jr T, Clark B, Hickman M, Grebely J, Campbell G, Sordo L . Association of Opioid Agonist Treatment With All-Cause Mortality and Specific Causes of Death Among People With Opioid Dependence: A Systematic Review and Meta-analysis. JAMA Psychiatry. 2021; 78(9):979-993. PMC: 8173472. DOI: 10.1001/jamapsychiatry.2021.0976. View

Wyse J, McGinnis K, Edelman E, Gordon A, Manhapra A, Fiellin D . Twelve-Month Retention in Opioid Agonist Treatment for Opioid Use Disorder Among Patients With and Without HIV. AIDS Behav. 2021; 26(3):975-985. PMC: 8840957. DOI: 10.1007/s10461-021-03452-0. View

MacArthur G, Minozzi S, Martin N, Vickerman P, Deren S, Bruneau J . Opiate substitution treatment and HIV transmission in people who inject drugs: systematic review and meta-analysis. BMJ. 2012; 345:e5945. PMC: 3489107. DOI: 10.1136/bmj.e5945. View

Ruglass L, Scodes J, Pavlicova M, Campbell A, Fitzpatrick S, Barbosa-Leiker C . Trajectory classes of opioid use among individuals in a randomized controlled trial comparing extended-release naltrexone and buprenorphine-naloxone. Drug Alcohol Depend. 2019; 205:107649. PMC: 6990451. DOI: 10.1016/j.drugalcdep.2019.107649. View

Paquette C, Daughters S, Witkiewitz K . Expanding the continuum of substance use disorder treatment: Nonabstinence approaches. Clin Psychol Rev. 2021; 91:102110. PMC: 8815796. DOI: 10.1016/j.cpr.2021.102110. View

Schiff D, Nielsen T, Hoeppner B, Terplan M, Hansen H, Bernson D . Assessment of Racial and Ethnic Disparities in the Use of Medication to Treat Opioid Use Disorder Among Pregnant Women in Massachusetts. JAMA Netw Open. 2020; 3(5):e205734. PMC: 7251447. DOI: 10.1001/jamanetworkopen.2020.5734. View

McGinnis K, Fiellin D, Skanderson M, Hser Y, Lucas G, Justice A . Opioid use trajectory groups and changes in a physical health biomarker among HIV-positive and uninfected patients receiving opioid agonist treatment. Drug Alcohol Depend. 2019; 204:107511. PMC: 6993986. DOI: 10.1016/j.drugalcdep.2019.06.014. View

Burgess-Hull A, Panlilio L, Preston K, Epstein D . Trajectories of craving during medication-assisted treatment for opioid-use disorder: Subtyping for early identification of higher risk. Drug Alcohol Depend. 2022; 233:109362. PMC: 8978588. DOI: 10.1016/j.drugalcdep.2022.109362. View

Hunter B, Jason L . Correlates of employment among men in substance use recovery: The influence of discrimination and social support. J Prev Interv Community. 2021; 50(2):163-177. PMC: 9148586. DOI: 10.1080/10852352.2021.1940756. View

10.

Frank D, Mateu-Gelabert P, Perlman D, Walters S, Curran L, Guarino H . "It's like 'liquid handcuffs": The effects of take-home dosing policies on Methadone Maintenance Treatment (MMT) patients' lives. Harm Reduct J. 2021; 18(1):88. PMC: 8364307. DOI: 10.1186/s12954-021-00535-y. View

11.

Fairley M, Humphreys K, Joyce V, Bounthavong M, Trafton J, Combs A . Cost-effectiveness of Treatments for Opioid Use Disorder. JAMA Psychiatry. 2021; 78(7):767-777. PMC: 8014209. DOI: 10.1001/jamapsychiatry.2021.0247. View

12.

Dong H, Hayashi K, Fairbairn N, Milloy M, DeBeck K, Wood E . Long term pre-treatment opioid use trajectories in relation to opioid agonist therapy outcomes among people who use drugs in a Canadian setting. Addict Behav. 2020; 112:106655. PMC: 7572870. DOI: 10.1016/j.addbeh.2020.106655. View

13.

Treitler P, Bowden C, Lloyd J, Enich M, Nyaku A, Crystal S . Perspectives of opioid use disorder treatment providers during COVID-19: Adapting to flexibilities and sustaining reforms. J Subst Abuse Treat. 2021; 132:108514. PMC: 8630075. DOI: 10.1016/j.jsat.2021.108514. View

14.

Buresh M, Genberg B, Astemborski J, Kirk G, Mehta S . Recent fentanyl use among people who inject drugs: Results from a rapid assessment in Baltimore, Maryland. Int J Drug Policy. 2019; 74:41-46. PMC: 6893143. DOI: 10.1016/j.drugpo.2019.08.006. View

15.

Hser Y, Huang D, Saxon A, Woody G, Moskowitz A, Matthews A . Distinctive Trajectories of Opioid Use Over an Extended Follow-up of Patients in a Multisite Trial on Buprenorphine + Naloxone and Methadone. J Addict Med. 2016; 11(1):63-69. PMC: 5291756. DOI: 10.1097/ADM.0000000000000274. View

16.

White W, Campbell M, Spencer R, Hoffman H, Crissman B, Dupont R . Patterns of abstinence or continued drug use among methadone maintenance patients and their relation to treatment retention. J Psychoactive Drugs. 2014; 46(2):114-22. DOI: 10.1080/02791072.2014.901587. View

17.

Bush K, Kivlahan D, McDonell M, Fihn S, Bradley K . The AUDIT alcohol consumption questions (AUDIT-C): an effective brief screening test for problem drinking. Ambulatory Care Quality Improvement Project (ACQUIP). Alcohol Use Disorders Identification Test. Arch Intern Med. 1998; 158(16):1789-95. DOI: 10.1001/archinte.158.16.1789. View

18.

Kim J, Lesko C, Fojo A, Keruly J, Moore R, Chander G . The Effect of Buprenorphine on Human Immunodeficiency Virus Viral Suppression. Clin Infect Dis. 2021; 73(11):1951-1956. PMC: 8664419. DOI: 10.1093/cid/ciab578. View

19.

Shah N, Galai N, Celentano D, Vlahov D, Strathdee S . Longitudinal predictors of injection cessation and subsequent relapse among a cohort of injection drug users in Baltimore, MD, 1988-2000. Drug Alcohol Depend. 2005; 83(2):147-56. DOI: 10.1016/j.drugalcdep.2005.11.007. View

20.

Lo-Ciganic W, Gellad W, Gordon A, Cochran G, Zemaitis M, Cathers T . Association between trajectories of buprenorphine treatment and emergency department and in-patient utilization. Addiction. 2015; 111(5):892-902. DOI: 10.1111/add.13270. View